Literature DB >> 28943042

Structure-activity relationship study of β-oxidation resistant indole-based 5-oxo-6,8,11,14-eicosatetraenoic acid (5-oxo-ETE) receptor antagonists.

Qiuji Ye1, Shishir Chourey1, Rui Wang1, Nagendra Reddy Chintam1, Sylvie Gravel2, William S Powell2, Joshua Rokach3.   

Abstract

5-Oxo-6,8,11,14-eicosatetraenoic acid (5-oxo-ETE) is formed from 5S-hydroxy-6,8,11,14-eicosatetraenoic acid (5-HETE) by the 5-lipoxygenase (5-LO) pathway under conditions associated with oxidative stress. 5-Oxo-ETE is an important pro-inflammatory mediator, which stimulates the migration of eosinophils via a selective G-protein coupled receptor, known as the OXE receptor (OXE-R). Previously, we designed and synthesized structural mimics of 5-oxo-ETE such as 1 using an indole scaffold. In the present work, we added various substituents at C-3 of this moiety to block potential β-oxidation of the 5-oxo-valerate side chain, and investigated the structure-activity relationships of the resulting novel β-oxidation-resistant antagonists. Cyclopropyl and cyclobutyl substituents were well tolerated in this position, but were less potent as the highly active 3S-methyl compound. It seems likely that 3-alkyl substituents can affect the conformation of the 5-oxovalerate side chain containing the critical keto and carboxyl groups, thereby affecting interaction with the OXE-receptor.
Copyright © 2017. Published by Elsevier Ltd.

Entities:  

Keywords:  5-Oxo-ETE; Antagonist; Asthma; Eosinophil; Structure-activity relationship

Mesh:

Substances:

Year:  2017        PMID: 28943042     DOI: 10.1016/j.bmcl.2017.08.034

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  1 in total

1.  ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model.

Authors:  Yuzo Iwaki; Akira Ohhata; Shingo Nakatani; Katsuya Hisaichi; Yasuyuki Okabe; Atsushi Hiramatsu; Toshihide Watanabe; Shingo Yamamoto; Taihei Nishiyama; Juta Kobayashi; Yasuo Hirooka; Hideki Moriguchi; Tatsuo Maeda; Makoto Katoh; Yuka Komichi; Hiroto Ota; Naoya Matsumura; Masahiro Okada; Tetsuya Sugiyama; Hiroshi Saga; Akira Imagawa
Journal:  ACS Med Chem Lett       Date:  2020-05-14       Impact factor: 4.345

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.